Prostate PET-CT imaging with 18F-PSMA
Access enhanced prostate imaging at our PET-CT centres across the UK.
The 18F-PSMA tracer is now available at all our PET-CT centres, helping to meet demand for early detection of local and systemic spread of prostate cancer.
Highly sensitive, this innovative tracer is designed to detect very small prostate cancer lesions, allowing for earlier detection and more accurate staging - crucial for accurate treatment planning.
A significant body of literature highlights the remarkable benefits of an 18F-PSMA PET-CT scan - especially in cases of Prostate Cancer recurrence - even in scenarios with low and high PSA levels where previous PET-CT FEC scans had been negative. This significantly enhances our ability to identify and address cancer progression at its earliest stages.
To discuss availability and find out more contact petct@alliance.co.uk, refer your patient today, or read more in our case study highlighting the impact of 18F-PSMA.
Highly sensitive, this innovative tracer is designed to detect very small prostate cancer lesions, allowing for earlier detection and more accurate staging - crucial for accurate treatment planning.
A significant body of literature highlights the remarkable benefits of an 18F-PSMA PET-CT scan - especially in cases of Prostate Cancer recurrence - even in scenarios with low and high PSA levels where previous PET-CT FEC scans had been negative. This significantly enhances our ability to identify and address cancer progression at its earliest stages.
To discuss availability and find out more contact petct@alliance.co.uk, refer your patient today, or read more in our case study highlighting the impact of 18F-PSMA.
Key Benefits of 18F-PSMA:
- High Target Specificity: accurate identification of prostate-specific markers.
- Enhanced Sensitivity: improved detection capabilities for early-stage prostate cancer.
- Lower Radiation Exposure: ensuring patient safety without compromising imaging quality.
- Accurate Staging: precise determination of cancer progression.
Make a referral
Simply fill in our form and our friendly team will get your patient booked in.
Have a question? Email us at petct@alliance.co.uk
%201.svg){kind=icon}
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Case Study: 18F-PSMA PET-CT scan
A significant amount of scientific literature focuses on the benefits of 18F-PSMA PET-CT scan, particularly on
early detection of Prostate Ca recurrence on low and high PSA levels when PET-CT FEC scan has previously been negative.
early detection of Prostate Ca recurrence on low and high PSA levels when PET-CT FEC scan has previously been negative.
Patient History
Male, 60 years old with previous Cystoprostatectomy for Bladder Ca, Prostate Ca and with post-operative increase PSA 16. No bone metastases confirmed on previous Bone scan.
Scan Findings
Initial 18F Choline PET-CT, completed 8 months post-surgery showed high uptake in the known tumour at the apex of the prostate gland on the right consistent with known primary tumour. There were tiny lymph nodes in the pelvis as described with only low-grade increased uptake.
The adrenal nodules show increased uptake on choline but are unchanged in size since the previous CT scan.
The adrenal nodules show increased uptake on choline but are unchanged in size since the previous CT scan.
18F-PSMA PET-CT Scan
Completed 9 months post-surgery showed findings consistent with a tumour in the prostate gland. In view of positivity seen on both 18F Choline and 18F-PSMA PET-CT in a left common iliac chain lymph node and uptake in the bony pelvis, particularly on the left, the findings are highly suspicious of metastatic disease, not detected in previous imaging.
Conclusion
Both areas of disease, previously known and metastatic disease found in the 18F-PSMA PET-CT scan, can be treated increasing chances of positive prognosis.
PET-CT Whole Body FEC
PET-CT Whole Body 18F-PSMA
